explore -WSS

explore

author：Wikipedia 2025-09-30 15:22:31 - browse：99922

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Unmasking the 'centricity' illusion in clinical trials

WSS

Medicare says breakthrough device reimbursement rule to come by summer

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Decentralized clinical trials need collaboration to achieve wider use

CDC wastewater surveillance dashboard to track bird flu hotspots

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Louisiana bill approved classifying abortion pills as controlled substances

hotspot

explore

entertainment

Medical records are filled with copy

Shionogi licenses Pompe disease therapy from Maze Therapeutics

The cancer drug shortage isn’t new — and neither are the solutions

Bird flu makes raw milk dangerous to consume, mouse study finds

As demand for Covid shots wanes, Moderna seeks its next success

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

At least 13 dead in Texas as scorching temps continue

How to improve immunocompromised access to mAb treatments

Malaria cases in Florida and Texas: Here’s what you need to know

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Wikipedia

Unmasking the 'centricity' illusion in clinical trials

What nurses really want: sufficient staffing for patient care

Beyond aggravation: Constipation is an American epidemic

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Congress: Prevent baby formula shortages by passing a new bill

Achieving telehealth equity for people with hearing loss

knowledge

hotspot

Wikipedia

hotspot